Precocious Puberty Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the Market

Delveinsight Business Research LLP

DelveInsight’s “Precocious Puberty Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Precocious Puberty, historical and forecasted epidemiology as well as the Precocious Puberty market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

The Precocious Puberty market report provides current treatment practices, emerging drugs, Precocious Puberty market share of the individual therapies, and current and forecasted Precocious Puberty market size from 2019 to 2032 segmented by seven major markets. The Report also covers current Precocious Puberty treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Precocious Puberty Overview

Precocious puberty is when a child’s body begins changing into that of an adult (puberty) too soon. When puberty begins before age 8 in girls and before age 9 in boys, it is considered precocious puberty. Puberty includes rapid growth of bones and muscles, changes in body shape and size, and development of the body’s ability to reproduce. The cause of precocious puberty often can’t be found. Rarely, certain conditions, such as infections, hormone disorders, tumors, brain abnormalities or injuries, may cause precocious puberty. Treatment for precocious puberty typically includes medication to delay further development.

Precocious Puberty Epidemiology Insights

• The first epidemiologic study from a Danish national registry estimated that 0.2 % of females had some form of precocious puberty (CPP, PPP or benign variants) while it was less than 0.05% in males. There was a female predominance of about 20 to 23 per 10000 girls compared to boys, which was less than 5 per 10000 boys

• A total of 37 890 girls and 1220 boys were newly registered with a diagnosis of central precocious puberty from 2008 to 2014. The overall incidence of central precocious puberty during the study period was 122.8 per 100 000 persons (girls, 262.8; boys, 7.0). The overall prevalence of central precocious puberty during the study period was 193.2 per 100 000 persons (girls, 410.6; boys, 10.9). The incidence and prevalence of central precocious puberty steeply increased during the study period in both girls and boys.

Precocious Puberty Epidemiology Segmentation

• Precocious puberty prevalent cases 

• Precocious puberty age-specific cases

• Precocious puberty gender-specific cases

Precocious Puberty Market Outlook 

The Precocious Puberty market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Precocious Puberty market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Precocious Puberty market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Precocious Puberty market in 7MM is expected to change in 2019-2032.

Learn more by requesting for sample @ Precocious Puberty Market Trends

Precocious Puberty Key Companies 

• Takeda 

• Abbvie 

• Ipsen 

• Endo Pharmaceuticals 

• AstraZeneca 

• And many others

Precocious Puberty Therapies

• Leuprolide Acetate

• Triptorelin Pamoate

• GnRH agonist

• Histrelin Subcutaneous Implant

• Leuprolide Mesylate,

Table of Contents

1.  Key Insights 

2.  Report Introduction 

3.  Executive Summary of Precocious Puberty    

4.  Disease Background and Overview

5.  Epidemiology and patient population 

6.  Precocious Puberty Emerging Therapies

7.  Precocious Puberty Market Outlook

8.  Market Access and Reimbursement of Therapies

9.  Market Drivers 

10.  Market Barriers 

11.  Appendix

12.  Precocious Puberty Report Methodology

13.  DelveInsight Capabilities

14.  Disclaimer

Click here to read more about Precocious Puberty Market 

Related Reports 

Central Precocious Puberty Pipeline Insights, 2022

Central Precocious Puberty Pipeline Insights, 2022″ report by DelveInsight outlays comprehensive insights of the present clinical development scenario and growth prospects across the Precocious Puberty market. A detailed picture of the Precocious Puberty pipeline landscape is provided, which includes the disease overview and Precocious Puberty treatment guidelines. The assessment part of the report embraces in-depth Precocious Puberty commercial assessment and clinical assessment of the Precocious Puberty pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Precocious Puberty collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com